CART-EGFR-IL13Ra2 in Newly Diagnosed GBM Following Initial Radiotherapy
Running, not enrolling · Phase 1
Conditions studied: Glioblastoma
In brief
This is an open-label phase 1 study to assess the safety, feasibility, pharmacokinetics and preliminary efficacy of autologous T cells co-expressing two CARs targeting the cryptic EGFR epitope 806 and IL13Ra2 (referred to as "CART-EGFR-IL13Ra2 cells") in patients with newly diagnosed, EGFR-amplified, MGMT-unmethylated glioblastoma, without evidence of disease recurrence/progression following completion of initial radiotherapy.
Key facts
- Study ID
- NCT06973096
- Run by
- University of Pennsylvania
- People needed
- 9
- Starts
- 2025-07-18
- Expected to finish
- 2042-07-01
- Last updated by the study team
- 2026-07-22
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- University of Pennsylvania — Philadelphia, Pennsylvania, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.